Atrial fibrillation in patient with high thrombotic risk: which therapy?

Fibrillazione atriale in paziente a elevato rischio trombotico: quale terapia?

  • Gabriele Dell'Era Cardiologia 1, AOU Maggiore della Carità, Novara - Italy
Keywords: Atrial fibrillation, Dabigatran, High thrombotic risk, High hemorrhagic risk

Abstract

We report the case of an elderly patient suffering for about 20 years of hypertensive cardiac hypertrophy, carotid and peripheral vasculopathy. The patient, initially treated with oral anticoagulant therapy (dicumarol) due to relapsing atrial fibrillation, is an example of long-term use of dabigatran, dictated by safety concern in a patient at high risk of bleeding: as demonstrated by the RE-LY trial, dabigatran 110 mg / day has a preventive effect on cerebral events similar warfarin but with a lower incidence of bleeding. In this case, at high risk both thrombotic and hemorrhagic, the choice of dabigatran was successful in the long term (Cardiology).

Published
2018-10-24
How to Cite
Dell’EraG. (2018). Atrial fibrillation in patient with high thrombotic risk: which therapy?. AboutOpen, 4(1), 174-178. https://doi.org/10.19156/abtpn.2018.0069